82 related articles for article (PubMed ID: 8472118)
41. Alpha/beta value and the importance of size of dose per fraction for late complications in the supraglottic larynx.
Maciejewski B; Taylor JM; Withers HR
Radiother Oncol; 1986 Dec; 7(4):323-6. PubMed ID: 3809591
[TBL] [Abstract][Full Text] [Related]
42. The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy.
Slevin NJ; Hendry JH; Roberts SA; Agren-Cronqvist A
Radiother Oncol; 1992 Aug; 24(4):215-20. PubMed ID: 1410576
[TBL] [Abstract][Full Text] [Related]
43. The effect of differing radiotherapeutic schedules on the response of glottic carcinoma of the larynx.
Robertson AG; Robertson C; Boyle P; Symonds RP; Wheldon TE
Eur J Cancer; 1993; 29A(4):501-10. PubMed ID: 8435200
[TBL] [Abstract][Full Text] [Related]
44. Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx.
Overgaard J; Hjelm-Hansen M; Johansen LV; Andersen AP
Acta Oncol; 1988; 27(2):147-52. PubMed ID: 3390345
[TBL] [Abstract][Full Text] [Related]
45. Linear-quadratic analysis of tumour response to fractionated radiotherapy: a study on human squamous cell carcinoma xenografts.
Petersen C; Baumann M; Dubben HH; Arps H; Melenkeit A; Helfrich J
Int J Radiat Biol; 1998 Feb; 73(2):197-205. PubMed ID: 9489567
[TBL] [Abstract][Full Text] [Related]
46. The influence of radiotherapy treatment time on the control of laryngeal cancer: a direct analysis of data from two British Institute of Radiology trials to calculate the lag period and the time factor.
Roberts SA; Hendry JH; Brewster AE; Slevin NJ
Br J Radiol; 1994 Aug; 67(800):790-4. PubMed ID: 8087485
[TBL] [Abstract][Full Text] [Related]
47. Adverse effect of treatment gaps in the outcome of radiotherapy for laryngeal cancer.
Duncan W; MacDougall RH; Kerr GR; Downing D
Radiother Oncol; 1996 Dec; 41(3):203-7. PubMed ID: 9027934
[TBL] [Abstract][Full Text] [Related]
48. Early skin reactions in head and neck malignancy treated by twice-daily fractionated radiotherapy--estimation of alpha/beta of LQ model.
Chougule A; Supe SJ
Phys Med Biol; 1993 Sep; 38(9):1335-42. PubMed ID: 8415904
[TBL] [Abstract][Full Text] [Related]
49. Effect of gap length and position on results of treatment of cancer of the larynx in Scotland by radiotherapy: a linear quadratic analysis.
Robertson AG; Robertson C; Perone C; Clarke K; Dewar J; Elia MH; Hurman D; MacDougall RH; Yosef HM
Radiother Oncol; 1998 Aug; 48(2):165-73. PubMed ID: 9783888
[TBL] [Abstract][Full Text] [Related]
50. Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers.
Robertson C; Robertson AG; Hendry JH; Roberts SA; Slevin NJ; Duncan WB; MacDougall RH; Kerr GR; O'Sullivan B; Keane TJ
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):319-29. PubMed ID: 9457816
[TBL] [Abstract][Full Text] [Related]
51. Dose response of squamous cell carcinomas of the upper respiratory and digestive tracts.
Thames HD; Peters LJ; Spanos W; Fletcher GF
Br J Cancer Suppl; 1980 Apr; 4():35-8. PubMed ID: 6775658
[TBL] [Abstract][Full Text] [Related]
52. Radiation treatment of laryngeal carcinoma with special reference to CRE values.
Underskog I; Sorbe B; Persson JE
Acta Radiol Oncol; 1985; 24(3):227-32. PubMed ID: 2994371
[TBL] [Abstract][Full Text] [Related]
53. Response of human tumour xenografts to fractionated X-irradiation.
Lindenberger J; Hermeking H; Kummermehr J; Denekamp J
Radiother Oncol; 1986 May; 6(1):15-27. PubMed ID: 3715059
[TBL] [Abstract][Full Text] [Related]
54. Time factors in larynx tumor radiotherapy: lag times and intertumor heterogeneity in clinical datasets from four centers.
Roberts SA; Hendry JH
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1247-57. PubMed ID: 10613320
[TBL] [Abstract][Full Text] [Related]
55. Volume and heterogeneity dependence of the dose-response relationship for head and neck tumours.
Agren Cronqvist AK; Källman P; Turesson I; Brahme A
Acta Oncol; 1995; 34(6):851-60. PubMed ID: 7576755
[TBL] [Abstract][Full Text] [Related]
56. Laryngeal carcinoma. IV. Analysis of treatment results using the Cohen model.
Hjelm-Hansen M
Acta Radiol Oncol; 1980; 19(1):3-12. PubMed ID: 6246727
[TBL] [Abstract][Full Text] [Related]
57. Re-analysis of the time factor in local control by radiotherapy of T3T4 squamous cell carcinoma of the larynx.
Lindstrom MJ; Fowler JF
Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):813-7. PubMed ID: 1831192
[TBL] [Abstract][Full Text] [Related]
58. A comparison of the normal-tissue reactions in patients treated with either 3F/Wk or 5F/Wk in the BIR (British Institute of Radiology) trial of radiotherapy for carcinoma of the laryngo-pharynx.
Rezvani M; Alcock CJ; Fowler JF; Haybittle JL; Hopewell JW; Wiernik G
Int J Radiat Biol; 1989 Nov; 56(5):717-20. PubMed ID: 2573668
[No Abstract] [Full Text] [Related]
59. Response to Lindstrom and Fowler's "The influence of dose and time on local control of carcinoma of the larynx by radiation therapy".
Baumann M; Beck-Bornholdt HP
Int J Radiat Oncol Biol Phys; 1992; 22(5):1163. PubMed ID: 1555971
[No Abstract] [Full Text] [Related]
60. The sensitivity of human tissues to changes in dose fractionation: deductions from the RCR survey among UK radiotherapists.
Hendry JH; Roberts SA
Clin Oncol (R Coll Radiol); 1991 Jan; 3(1):22-7. PubMed ID: 2001338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
